Novartis trial shows drug improves survival for AML patients

ZURICH (Reuters) - Novartis' phase III study for its acute myeloid leukemia (AML) drug showed it improved overall survival by 23 percent for patients with FLT3 mutations, the Swiss drugmaker said on Sunday.

http://ift.tt/1OI6Gxk

from Reuters: Health News
via animenewspro